Viewing Study NCT01245166


Ignite Creation Date: 2025-12-24 @ 4:37 PM
Ignite Modification Date: 2025-12-30 @ 3:54 PM
Study NCT ID: NCT01245166
Status: UNKNOWN
Last Update Posted: 2010-11-22
First Post: 2010-11-19
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase III Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Acarmet (Metformin HCl 500 mg Plus Acarbose 50 mg Tablets) Versus Acarbose Alone in Subjects With Type 2 Diabetes Mellitus
Sponsor: Lotus Pharmaceutical
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None The Objectives of the Study is to Evaluate the Efficacy … View
None Plus Acarbose 50 mg Tablets) Thrice Daily Versus Acarbose 50 … View
None Subjects With Type 2 Diabetes Mellitus. View
Keywords: